OFIX Orthofix Medical Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 884624 · Fiscal year ends 12/23
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.1%
TTM net income YoY62.2%
TTM EPS YoY63.7%
Revenue 3-yr CAGR7.7%
Net income 3-yr CAGR—
Margins
Gross margin70.9%
Operating margin-2.5%
Net margin-5.4%
FCF margin-5.3%
EBITDA margin3.9%
Returns
ROE-10.3%
ROA-5.3%
ROIC (approx.)-2.9%
Asset turnover0.99x
Leverage & solvency
Liabilities / assets49.8%
Debt / equity0.52x
Current ratio3.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.09x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue5.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $207.86M | $210.93M | $196.71M | $219.91M | $205.63M | $203.12M | $193.65M | $215.66M |
| Cost of revenue | $61.32M | $61.23M | $57.16M | $63.57M | $57.11M | $63.59M | $72.03M | $66.82M |
| Gross profit | $146.55M | $149.71M | $139.55M | $156.34M | $148.52M | $139.53M | $121.62M | $148.84M |
| R&D expense | $15.28M | $15.94M | $15.32M | $15.37M | $14.77M | $15.93M | $19.77M | $18.81M |
| SG&A expense | $125.33M | $138.03M | $134.91M | $136.75M | $148.10M | $136.49M | $132.98M | $433.32M |
| Operating income | $1.54M | -$8.13M | -$14.44M | $494,000 | -$17.05M | -$16.00M | -$48.87M | -$11.48M |
| Pretax income | -$5.25M | -$15.00M | -$20.83M | -$2.19M | -$22.26M | -$14.22M | -$52.13M | -$29.71M |
| Income tax | $826,000 | $801,000 | $74,000 | $30,000 | $533,000 | -$142,000 | $961,000 | -$564,000 |
| Net income | -$6.07M | -$15.80M | -$20.91M | -$2.22M | -$22.80M | -$14.08M | -$53.09M | -$29.15M |
| EBITDA | $14.72M | $5.14M | -$943,000 | $13.57M | -$4.11M | $868,000 | -$14.44M | $4.52M |
| EPS (basic) | -0.15 | -0.39 | -0.52 | — | -0.57 | -0.36 | -1.35 | — |
| EPS (diluted) | -0.15 | -0.39 | -0.52 | — | -0.57 | -0.36 | -1.35 | — |
| Weighted avg. shares (diluted) | 41.18M | 40.91M | 40.45M | — | 39.77M | 39.50M | 39.19M | — |
| Banking | ||||||||
| Net interest income | -$5.89M | -$6.08M | -$5.66M | -$4.35M | -$4.68M | -$3.95M | -$4.51M | -$14.92M |
| Provision for credit losses | $1.24M | $2.87M | $719,000 | -$211,000 | $629,000 | $779,000 | $1.06M | -$60,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $86.32M | $103.81M | $120.28M | $82.03M | $62.86M | $65.61M | $57.95M | $83.24M |
| Receivables | $131.72M | $135.82M | $137.78M | $135.75M | $130.81M | $129.56M | $131.87M | $134.71M |
| Inventory | $190.36M | $184.47M | $177.82M | $172.32M | $174.04M | $172.99M | $174.48M | $189.45M |
| Current assets | $430.79M | $446.13M | $461.52M | $416.85M | $394.17M | $395.83M | $390.31M | $433.29M |
| PP&E, net | $133.39M | $130.76M | $125.33M | $129.40M | $130.02M | $129.20M | $130.69M | $139.80M |
| Goodwill | $194.93M | $194.93M | $194.93M | $194.93M | $194.93M | $194.93M | $194.93M | $194.93M |
| Intangibles | $62.90M | $65.97M | $69.34M | $72.77M | $75.64M | $78.87M | $81.21M | $98.80M |
| Total assets | $855.76M | $873.02M | $886.60M | $850.65M | $832.61M | $837.16M | $823.14M | $893.29M |
| Current liabilities | $138.38M | $157.01M | $161.03M | $170.48M | $159.85M | $148.38M | $144.12M | $168.63M |
| Short-term debt | — | — | — | $0 | — | — | — | $0 |
| Long-term debt | $221.85M | $221.59M | $221.34M | $157.39M | $157.22M | $157.05M | $156.88M | $157.01M |
| Total debt | $221.85M | $221.59M | $221.34M | $157.39M | $157.22M | $157.05M | $156.88M | $157.01M |
| Total liabilities | $426.19M | $443.84M | $451.42M | $400.61M | $390.12M | $378.81M | $364.85M | $390.17M |
| Shareholders' equity | $429.57M | $429.18M | $435.19M | $450.04M | $442.49M | $458.35M | $458.29M | $503.12M |
| Net debt | $135.53M | $117.78M | $101.06M | $75.37M | $94.36M | $91.44M | $98.93M | $73.78M |
| Shares outstanding | 40.75M | 40.73M | 40.38M | 39.83M | 39.52M | 39.48M | 39.10M | 38.49M |
| Cash flow statement | ||||||||
| Operating cash flow | $363,000 | -$6.22M | -$17.61M | $27.70M | $12.40M | $11.64M | -$18.39M | $23.73M |
| Capital expenditure | $14.50M | $12.65M | $10.66M | $10.88M | $9.90M | $7.11M | $6.74M | $9.67M |
| Free cash flow | -$14.14M | -$18.87M | -$28.27M | $16.82M | $2.50M | $4.53M | -$25.13M | $14.06M |
| Investing cash flow | -$14.50M | -$12.65M | -$10.52M | -$10.87M | -$9.89M | -$7.10M | -$6.74M | -$1.14M |
| Financing cash flow | -$3.19M | $2.45M | $63.97M | $2.38M | -$5.15M | $2.64M | -$651,000 | $31.49M |
| Depreciation & amortization | $13.17M | $13.27M | $13.49M | $13.08M | $12.94M | $16.87M | $34.43M | $15.99M |
| Stock-based compensation | $6.74M | $7.74M | $6.53M | $7.21M | $7.18M | $7.82M | $6.47M | $7.17M |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.